Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the filing of a ...

Raanana, Israel - Polyrizon Ltd. (NASDAQ:PLRZ), a biotech firm in the development stage, has filed a divisional patent application in Israel for its Trap & Target (NYSE:TGT) (T&T) platform technology.

Polyrizon (PLRZ) announced the filing of a divisional patent application with the Israel Patent Office for its Trap & Target platform ...

Biopharmaceutical Drug Delivery Technologies Market The global biopharmaceutical drug delivery technologies <a target=_blank href=https: ...

Ethris announces promising phase 1 results for ETH47, its mRNA therapy for uncontrolled asthma. The inhaled treatment showed strong safety and efficacy, with plans for a phase 2 trial in 2025.

Ethris GmbH, a leading biotechnology company pioneering next-generation RNA therapeutics and vaccines, today announced promising topline data from the completed Phase 1 clinical trial of its lead mRNA ...

The floating nuclear power plant in the concept phase intends to serve a non-specific port in the Southern United States ...

The Council on American-Islamic Relations, the nation’s largest Muslim civil rights and advocacy organization, on Wednesday ...

Court documents show more details about what investigators believe happened in a string of vandalism over the weekend and why some of the incidents are charged as hate crimes.